Mortality and β-agonists, or the risk of statistical inference;Mortalidad por betaagonistas o el riesgo de la inferencia

Archivos de Bronconeumologia

Volumn 43, Issue 7, 2007, Pages 355-357

  Domingo Ribas, Christian ^a,b,c  

^a PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Servicio de Oncología Médica   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FENOTEROL; FORMOTEROL; PLACEBO; SALBUTAMOL; SALMETEROL;

EDITORIAL; HUMAN; MORTALITY; RISK;

EID: 34548455414     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S1579-2129(07)60085-8     Document Type: Editorial

References (16)

1. Inman WH, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurized aerosols. Lancet. 1969;2:279-85.
2. Crane J, Perace N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-1983: a case-control study. Lancet. 1989;1:917-22.
3. Pearce N, Grainger J, Atkinson M, et al. Case control study of prescribed fenoterol and death from asthma in New Zeeland, 1977-1981. Thorax. 1990;45:170-5.
4. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zeeland 1981-1987: a further case-control study. Thorax. 1991;46:105-11.
5. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326:501-6.
6. Castle W, Fuller R, Hall J, Palmer J. Serevent Nationwide Surveillance Study: comparison of salmetrol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034-7.
7. 2-agonists. Eur Respir J. 2006;28:900-2.
8. Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial. Chest. 2006;129:15-26.
9. Wolfe J, Laforce C, Friedman B, et al. Formoterol, 24 μg bid, and serious asthma exacerbations. Similar rates compared with formoterol, 12 μg bid with and without extra doses taken on demand, and placebo. Chest. 2006;129:27-38.
10. Benchs G, Lapidus R, Levine B, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol. 2001;86:19-27.
11. Benchs G, Berger W, Blokhin M, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol. 2002;89:180-90.
12. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma related deaths. Ann Intern Med. 2006;144: 904-12.
13. Kallergis EM, Manios EG, Kanoupakis EM, et al. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest. 2005;127:2057-63.
14. Salpeter SR, Ormission TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD. A meta-analysis. Chest. 2004;125:2309-21.
15. 2- adrenoreceptor agonists. Cardiovascular safety in patients with obstructive lung disease. Drugs. 2005;66:1595-610.
16. Domingo C, Navarro M, Comet R, et al. Effect of early versus late intervention with inhaled corticosteroid in bronchial asthma: pulmonary function benefits and side-effects at the end of a threemonth follow-up. Eur Respir J. 1998;12 Suppl 29:81.